sofie van gijsel

Director Investor Relations @ Galapagos

[Lakefront Biotherapeutics @LakefrontBio]

Press release: https://t.co/3M8wCdJ7U0 | Solid H1 with strong commercial progress and important first steps to rebuild our portfolio. Our first medicine shows robust performance, leading us to raise our full-year net sales guidance. #PioneeringForPatients $glpg

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | Galapagos demonstrates regulatory and commercial progress in Q1 2022. Read the full press release here: https://t.co/31OkJsKChL $glpg

[Lakefront Biotherapeutics @LakefrontBio]

Discover our Annual Report here➡️https://t.co/Q4NvuuQYdP

[Lakefront Biotherapeutics @LakefrontBio]

Press release | Galapagos 2021 results set stage for future growth. Read the full press release here: https://t.co/rIuNg6hlxz

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | Galapagos announces its Q1 results and presents refocused pipeline. Read the press release here https://t.co/lzjPHKB3pN

[Lakefront Biotherapeutics @LakefrontBio]

Galapagos is proud to be included in the 2021 @Bloomberg Gender-Equality Index (GEI), which brings transparency to gender-related practices & policies at publicly listed companies. Diversity & inclusion are essential in #PioneeringForPatients! #BloombergGEI #GenderEquality $glpg

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | @GileadSciences and Galapagos announce new commercialization and development agreement for #RheumatoidArthritis (RA) treatment. Read more here: https://t.co/FCNGXs7jzL #PioneeringForPatients

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | Galapagos announces first dosing in MANGROVE Phase 2 trial for investigational treatment in autosomal dominant polycystic kidney disease (ADPKD). For more information: https://t.co/8o7v4NLK4j #PioneeringForPatients

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | Galapagos reports topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial. Read the full press release here: https://t.co/eP45j9hMNB. #IPF #Fibrosis #PioneeringForPatients

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | Selvita (@SelvitaKrakow) to acquire Fidelta. Fidelta continues performing drug discovery services for Galapagos for the next five years. ➡️ Read our press release here: https://t.co/OXDgFgTuzj

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial. Read more here ➡️ https://t.co/VCBZ6Tlog1 #PioneeringForPatients #Inflammation #Psoriasis

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | @oncoarendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis. This collaboration strengthens & complements our fibrosis portfolio. Read more here 👉 https://t.co/hERV9m91Zi #PioneeringForPatients #PioneeringForIPF #IPF #Fibrosis

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | @EMA_News accepts regulatory application for Galapagos’ and Gilead’s treatment for patients with ulcerative colitis. Read the full press release here: https://t.co/F3VfbTVbDr #UC #PioneeringForPatients

[Lakefront Biotherapeutics @LakefrontBio]

It's Open Access Week ! Galapagos has committed to making its published scientific research freely accessible to everyone. Find out more on our website: https://t.co/dZ6LT2Inzf #OAWeek

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | Galapagos’ R&D Roundtable showcases Toledo program with salt-inducible kinase inhibitors (SIKs), unveiling #Toledo target. ➡️ Read more here: https://t.co/NtMwMnbPaE #PioneeringForPatients #SIK #Inflammation #Fibrosis

[Lakefront Biotherapeutics @LakefrontBio]

Join us for our Toledo R&D Roundtable! #PioneeringForPatients
📅 27 October 2020
⏰ 16:00 CET / 11:00 EST
⏳ 1h 30 m
✍ Register here: https://t.co/iyBzY6KaH8

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial. Dr. Piet Wigerinck (CSO): “We are excited by the rapid progress of GLPG3970 in the clinic.” Read more here: https://t.co/MprtjSWASw #PioneeringForPatients

[sofie van gijsel @sofievangijsel]

EC marketing authorization granted for @GileadSciences’ and @GalapagosGlobal #RA treatment: https://t.co/P74iPmgnih

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | @EU_Commission grants marketing authorization for @GileadSciences’ and Galapagos’ #RheumatoidArthritis treatment. Find out more here: https://t.co/MprtjSWASw

[Onno van de Stolpe @OvandeStolpe]

Jyseleca approved in Japan! Our first medicine from target discovery to approval. A hallmark moment for #GLPG. A big thank you to all the colleagues who have made this possible. I am very proud!

[sofie van gijsel @sofievangijsel]

Topline results of NOVESA trial in dcSSc patients announced: https://t.co/P74iPmgnih $glpg $gild

[Lakefront Biotherapeutics @LakefrontBio]

Press Release | Galapagos reports topline results in the NOVESA Phase 2a clinical trial in patients with diffuse cutaneous systemic sclerosis (dcSSc). Read our release here: https://t.co/MprtjSWASw #PioneeringForPatients